Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (331-340 of 401) with videos related to

Pageof 41
Sort By:
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
Nature Reviews. Cardiology|January 19, 2020
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular diseaseDavide Capodanno, Deepak L Bhatt, John W Eikelboom, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 21, 2020
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trialMasafumi Ono, Mariusz Tomaniak, Wolfgang Koenig, et al.
Journal of the American College of Cardiology|April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery DiseaseMarc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 4, 2023
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)Eliano Pio Navarese, Antonio Landi, Angelo Oliva, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular PharmacologyDiana A Gorog, Jurriën M Ten Berg, Gianluca Campo, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2025
Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trialDenise Tiong, Natalia Pinilla-Echeverri, David A Wood, et al.
European Heart Journal. Acute Cardiovascular Care|March 31, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risksDiana A Gorog, Jurrien M Ten Berg, Gianluca Campo, et al.
Pageof 41

Showing results (331-340 of 401) with videos related to

Sort By:
Pageof 41
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
Nature Reviews. Cardiology|January 19, 2020
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular diseaseDavide Capodanno, Deepak L Bhatt, John W Eikelboom, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 21, 2020
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trialMasafumi Ono, Mariusz Tomaniak, Wolfgang Koenig, et al.
Journal of the American College of Cardiology|April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery DiseaseMarc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 4, 2023
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)Eliano Pio Navarese, Antonio Landi, Angelo Oliva, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular PharmacologyDiana A Gorog, Jurriën M Ten Berg, Gianluca Campo, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2025
Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trialDenise Tiong, Natalia Pinilla-Echeverri, David A Wood, et al.
European Heart Journal. Acute Cardiovascular Care|March 31, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risksDiana A Gorog, Jurrien M Ten Berg, Gianluca Campo, et al.
Pageof 41